SciSparc Gains Edge with European Patent Grant

TEL AVIV, Israel, May 31, 2024 – SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, announced the European Patent Office's approval of its patent application, "Compositions and Methods of Potentiating Antimicrobials." This follows the similar approval previously received from the United States Patent and Trademark Office. This latest patent enhances SciSparc’s intellectual property portfolio by extending the protection of its innovations globally, reinforcing its position in the pharmaceutical industry, and providing a competitive advantage.

The new patent covers pharmaceutical compositions and methods designed to enhance the effectiveness of antimicrobials while reducing their side effects. This is especially pertinent in the fight against antimicrobial and antibiotic resistance, a critical issue identified by the World Health Organization as a severe global threat. The innovation involves compositions that include antibiotics, cannabinoids, and optionally N-acylethanolamines, aimed at preventing biofilm formation and microbe-induced diseases.

SciSparc has been strategically expanding its patent portfolio throughout 2024, with notable patents granted in Canada and Europe. This proactive approach underscores the company's dedication to protecting its technological advancements on a global scale. SciSparc’s intellectual property now spans major markets, including the United States, Europe, Japan, Australia, and Israel, comprising nine patent families and two trademarks.

SciSparc Ltd. is managed by a seasoned team of executives and scientists, focused on developing cannabinoid-based pharmaceutical technologies. The company's drug development pipeline includes:

- SCI-110, targeting conditions such as Tourette Syndrome, Alzheimer's disease, and agitation.
- SCI-160, aimed at pain management.
- SCI-210, designed for treating Autism Spectrum Disorder (ASD) and status epilepticus.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!